Enteral Feeding Formulas Market Size, Share & Industry Analysis, By Product Type (Polymeric Formulas, Elemental Formulas, Modular Formulas, and Disease Specific Formulas), By Form (Liquid and Powder), By Route of Administration (Oral, Enteral, and Tube Feeding), By Age Group (Adult and Pediatrics), By Indication (Oncology, Neurological Disorders, Metabolic & Endocrine Disorders, Gastrointestinal Disorders, and Others) By End User (Hospitals & ASCs, Home Care Settings, Long-Term Care Facilities, and Others), and Regional Forecast, 2026-2034

The global enteral feeding formulas market size was valued at USD 8.31 billion in 2025. The market is projected to grow from USD 8.75 billion in 2026 to USD 13.79 billion by 2034, exhibiting a CAGR of 5.85% during the forecast period.

The enteral feeding formulas market is witnessing notable growth during the forecast period. The enteral feeding formulas are focused on providing specialized nutritional support to patients who are unable to consume food orally. The rising prevalence of chronic diseases such as cancer, neurological disorders, and gastrointestinal conditions often necessitates enteral nutrition.

The increasing burden of diseases and disease-related hospitalization heightened the adoption of these products due to increasing awareness about the importance of proper nutrition to propel the growth of the global enteral feeding formulas market.

• For instance, according to the data published in August 2024 by the National Breast Cancer Foundation, Inc. 2024, an estimated 310,720 women and 2,800 men are expected to be diagnosed with invasive breast cancer, and 1 in 8 women in the U.S. is expected to be diagnosed with breast cancer in her lifetime.

The market encompasses several major players, with Abbott and B. Braun at the forefront. The robust portfolio and strategic activities support the dominance of these companies in the market.

MARKET DYNAMICS

MARKET DRIVERS

Increasing Geriatric Population and Prevalence of Chronic Disease to Propel Market Growth

The increasing geriatric population is a major driver of the enteral feeding formulas market. The rising prevalence of chronic diseases such as cancer, neurological disorders, and gastrointestinal conditions, and difficulties in swallowing and digestive issues necessitate specialized nutritional support. Additionally, such conditions amplify the demand for enteral nutrition solutions, which provide essential nutrients directly to the stomach or intestines, making these factors key market drivers.

• For instance, in October 2025, as per the World Health Organization, the number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Such a rising number of the geriatric population with swallowing and digestive issues is expected to boost the demand for nutritious food.

MARKET RESTRAINTS

Risk of Complication Associated with Enteral Feeding to Restrict Market Growth

The risk of complications associated with enteral feeding, such as aspiration pneumonia, diarrhea, and gastrointestinal intolerance, poses significant concerns for healthcare providers. These risks may discourage clinicians from prescribing these products, thereby decreasing widespread adoption and restraining the enteral feeding formulas market growth.

• For instance, the British Association for Parenteral and Enteral Nutrition reported the complications associated with enteral feeding, such as reflux and vomiting, mouth discomfort, and diarrhea.

MARKET OPPORTUNITIES

Increased Demand for Home Enteral Adoption to Create Lucrative Growth Opportunities

The rising demand for home enteral feeding solutions presents a significant growth opportunity in the enteral feed formulas market, as it is easier, convenient, and safe for patients and caregivers to manage nutritional needs at home. Additionally, the increasing shift toward tube feeding to improve patient outcomes is encouraging key market players to focus on offering mobile devices for enteral feeding, creating lucrative growth opportunities.

• For instance, in May 2024, Rockfield Medical Devices received U.S. Food and Drug Administration clearance 510(k) for its Mobility+ Enteral Feeding System under the Over the Counter Clearance (OTC) use. This system is portable and lightweight and is designed for enteral feeding in users aged two years and older in clinical or home-care settings.

ENTERAL FEEDING FORMULAS MARKET TRENDS

Development of Plant-Based Products to Act As Key Market Trend

The development of plant-based products for enteral feeding is emerging as a significant trend in the global enteral feeding formulas market. Increasing consumer awareness of the health benefits associated with plant-derived ingredients and growing demand for sustainable and eco-friendly nutrition solutions are encouraging manufacturers to innovate with plant-based formulations.

• For instance, in September 2024, Nutricia unveiled its reformulated Nutrison core range of tube feeds at the 46th ESPEN Congress on Clinical Nutrition and Metabolism in Milan. The updated product has higher plant-based protein content, which also has specialized tube feeds designed to address malnutrition in patients unable to eat normally, for patients undergoing treatment for conditions such as head or neck cancer.

MARKET CHALLENGES

High Cost and Lack of Reimbursement Policies to Challenge Market Growth

A key challenge in the enteral feeding formulas market is the high costs associated with these specialized products and the absence of comprehensive reimbursement policies in many regions. This limits patient access in the middle-income population and restricts market expansion.

Download Free sample to learn more about this report.

Segmentation Analysis

By Product Type

Increasing Adoption of Polymeric Formulas to Propel Segmental Growth

The product type segment is divided into polymeric formulas, elemental formulas, modular formulas, and disease-specific formulas.

To know how our report can help streamline your business, Speak to Analyst

The polymeric formulas segment held a dominant portion of the enteral feeding formulas market share in 2025. The dominance is driven by increasing adoption of polymeric formulas due to their lower cost, favorable reimbursement coverage, and wide availability across hospital, long-term care, and home-care settings.

In addition, increasing product launches by key players are further boosting the segment growth.

• For instance, in May 2023, Otsuka Pharmaceutical Factory, Inc. announced the launch of new variants of "ENORAS Liquid for Enteral Use". It is a concentrated (1.6 kcal/mL) polymeric enteric nutrition formula.

The elemental formulas segment is expected to grow at a CAGR of 7.86% over the forecast period. 

By Form

Advantages of Liquid Formulas to Boost the Segment Growth

In terms of technology, the market is categorized into liquid and powder.

The liquid segment accounted for the largest portion of the market. In 2025, the segment is anticipated to dominate with an 84.8% share. The leadership is driven by the advantages of liquid formulation, which are ready-to-use and easy to administer via both tube and oral routes.

The powder segment is expected to grow at a CAGR of 7.80% over the forecast period.  

By Route of Administration

Increasing Adoption of Less Invasive Feeding  to Lead Oral Route Segments' Growth

Based on route of administration, the market is segmented into oral, enteral, and tube feeding.

The oral segment held a dominant position in 2025, accounting for a 55.6% market share. This dominance is attributed to its non-invasive nature and easy of administration, making it the preferred of deliver nutrition, when patients are able to swallow safely. Oral nutrition is widely used for long-term home care and chronic disease nutrition support.

The tube feeding segment is poised for growth, with a forecasted rate of 4.76% during the forecast period. The increasing focus on expanding tube-feeding options for patients who are unable to take medicine is boosting the segment’s growth.

• For instance, the U.S. Food and Drug Administration (FDA) approved nasogastric and gastrostomy tube administration for Spritam (levetiracetam) tablets for oral suspension.

By Age Group

Rising Geriatric Population and Chronic Diseases Boosted the Adults Segment Growth

Based on age group, the market is segmented into adults and pediatrics

The adults segment held the dominating position in 2025, accounting for 81.6% of the total market share. The dominance is driven by the rising geriatric population and increasing prevalence of chronic diseases, which increases the need for long-term nutritional support.

• In 2025, as per the U.S. Department of Health and Human Services, around 2,041,910 new cases of cancer were diagnosed in the U.S.

The pediatric segment is poised for steady growth, with a forecasted rate of 4.20% during the forecast period.

By Indication

Increasing Cancer Cases and Complications Associated with the Oncology Treatment Boosted the Segment Growth

Based on indication, the market is segmented into oncology, neurological disorders, metabolic & endocrine disorders, gastrointestinal disorders, and others.

The oncology segment held the maximum portion of the market in 2025, holding 25.60% of the total market share in 2025. The dominance is driven by the rising prevalence of cancer and increasing demand for enteral feeding due to complications associated with the treatment.

• For instance, as per the World Cancer Research Fund, there were 968,784 new cases of stomach cancer in 2022.

The neurological disorders segment is poised for growth, with a forecasted rate of 6.81% during the forecast period.

By End User

Hospital & ASCs Segment to Dominate due to Rising Hospitalization for Chronic Disease Treatment

Based on end user, the market is segmented into hospitals & ASCs, home care settings, long-term care facilities, and others.

In 2025, the hospital & ASCs segment is expected to witness a leading growth trajectory, accounting for 38.8% of the total share.  The rising number of hospitalizations for chronic disease treatment is one of the major factors propelling the segment’s growth in the market.

• For instance, in February 2025, as per the data published in The American Journal of Gastroenterology, in 2019, approximately 4 million hospital stays were associated with a primary digestive disease diagnosis, while 17 million stays involved any listed digestive disease diagnosis. The rate of hospitalization was 1,080 per 100,000 population for first-listed diagnoses and 4,493 per 100,000 population for all-listed diagnoses.

The home care settings segment is projected to grow at a CAGR of 7.77% during the study period.

Enteral Feeding Formulas Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2025, valued at USD 2.87 billion, and also took the leading share in 2026 with USD 3.00 billion. The dominance of North America in the market is driven by the rising geriatric population and increasing focus on offering proper nutrition to critically ill patients. In 2025, the U.S. market is estimated to reach USD 2.73 billion. The U.S. is expected to dominate the North America region's market. The prevalence of chronic diseases and the presence of key players with advanced product offerings are boosting the country’s growth in the market.

Europe and Asia Pacific are expected to experience notable growth in the coming years. The European region is projected to record a growth rate of 4.79% During the forecast period, the second-highest among all regions, and reach a valuation of USD 2.47 billion in the enteral feeding formulas market by 2025. Rising chronic diseases, with active government support to boost market growth in the region. Backed by these factors, countries including the U.K. are expected to record the valuation of USD 0.54 billion, Germany to record USD 0.50 billion, and France to record USD 0.39 billion in 2025. After Europe, the Asia Pacific market is estimated to reach USD 1.99 billion by 2025 and secure the position of the third-largest region in the market. In the region, India and China are both estimated to reach USD 0.35 billion and USD 0.36 billion, respectively, in 2025.

The Latin America and Middle East & Africa regions would witness a moderate growth in the market. The market in Latin America is expected to reach a valuation of USD 0.52 billion in 2025. Increasing focus of key players to shift their presence in the region to boost market growth, but at a slower rate. In the Middle East and Africa MEA, the GCC is set to reach a value of USD 0.22 billion by 2025.

COMPETITIVE LANDSCAPE

Key Industry Players

Expansion of Product Offering and Strong Research and Development Activities to Maintain Their Market Position

The global market exhibits a fragmented structure, with a large number of companies actively operating worldwide. Key players benefit from robust product offerings and strong research and development capabilities. Abbott and Nestlé Health Science are among the leading companies in the industry. Their extensive product portfolios and ongoing new product launches are anticipated to strengthen their market positions.

Additionally, other significant players, such as B. Braun and Otsuka Pharmaceutical Co., Ltd., are also prominent in the market. These companies are concentrating on providing a diverse range of liquid, powder-based products to expand their market presence.

LIST OF KEY ENTERAL FEEDING FORMULAS COMPANIES PROFILED

• Abbott (U.S.)
• Nestlé Health Science (Switzerland)
• Nutricia (France)
• Fresenius Kabi (Germany)
• Braun (Germany)
• Baxter (U.S.)
• Ajinomoto Co., Inc. (Japan)
• Otsuka Pharmaceutical Co., Ltd. (Japan)
• Kate Farms Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS

• June 2025: Elgan Pharma Ltd. and Chiesi Farmaceutici S.p.A. enrolled the first infants in the FIT-PIV Phase 3 clinical trial. This study is evaluating the safety and effectiveness of ELGN-2112, an investigational drug candidate aimed at treating intestinal malabsorption in preterm infants.
• January 2025: Otsuka Pharmaceutical Factory, Inc., launched ENOSOLID semi-solid for enteral use.
• October 2021: Abbott re-launched PediaSure Harvest and Ensure Harvest for patients relying on feeding tubes.
• July 2020: Baxter collaborated with VIPUN Medical to commercialize the VIPUN Gastric Monitoring System. This innovative system features a “smart” enteral feeding tube designed to measure stomach motility to help clinicians identify enteral feeding.
• February 2025: Cardinal Health launched Kangaroo OMNI Enteral Feeding Pump in Europe, Australia, and New Zealand.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation